Aumake Seals A$10 Million Global Distribution Deal with EZZ Life Sciences

Core Insights - Aumake Limited has entered a four-year exclusive global distribution agreement with EZZ Life Sciences, valued at a minimum of A$10 million, significantly expanding Aumake's market reach [1][9] - The agreement includes minimum purchase commitments and allows EZZ to retain intellectual property and brand control [1][2] Distribution Agreement Details - Aumake will manage global sales and distribution responsibilities, with a key condition that failure to meet minimum purchase requirements can lead to termination of exclusive rights [2] - The initial product lineup includes EZZ Glutathione Health Support, EZZ Vitality Boost, and EZZ Sleep, with potential for future product expansions [3] Strategic Alignment - This agreement supports Aumake's broader nutraceutical growth strategy and aligns with its upcoming Xenitra rebrand, potentially serving as a proof point for future collaborations [4] - The partnership is crucial for Aumake's strategic expansion into the China market, leveraging existing networks [4] Financial Context - For the year ended 30 June 2025, Aumake reported a net loss of A$3.4 million and operating cash outflows of A$4.26 million, with auditors noting material uncertainty related to going concern [5] - Aumake raised A$1.5 million in a recapitalisation, extending its funding runway to approximately 10 quarters [6] Market Entry Strategy - Aumake has obtained a Hong Kong pharmaceutical wholesale licence for cross-border OTC sales into China, with plans for up to five online stores [7] - The China OTC market is estimated at USD 230 billion annually, with significant growth in online sales [7] Revenue Opportunities - The exclusive distribution deal with EZZ Life Sciences represents a significant revenue opportunity for Aumake, providing a minimum A$10 million floor [9] - Investors will monitor Aumake's execution closely, especially in light of its historical financial challenges and the need for sustainable profitability [9]